NASDAQ$CRNX
Crinetics Pharmaceuticals Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Crinetics reported financial results for Q4 and Full Year 2019 and provided a corporate update.
Crinetics Pharmaceuticals reported a net loss of $14.5 million for the fourth quarter of 2019, compared to a net loss of $8.5 million for the same period in 2018. Research and development expenses were $12.1 million, and general and administrative expenses were $3.4 million. Unrestricted cash, cash equivalents, and investments totaled $118.4 million as of December 31, 2019.
- Dosed first patients in Phase 2 clinical trials of paltusotine for acromegaly.
- Initiated Phase 1 trial of CRN01941 for neuroendocrine tumors.
- Expanded management team and board of directors.
- Cash, cash equivalents and investments will fund its current operating plan into the second half of 2021.
Headline financials
Revenue & EPS history
Crinetics · Revenue · Quarterly
$321K
Revenue by segment
Crinetics · $1.1M total across 1 segment · Q4 2021
- Collaboration and license$1.1M—100.0%
Forward guidance
Crinetics plans to provide guidance on timing of its acromegaly and neuroendocrine tumor programs early in the second quarter and is advancing its ACTH antagonist development candidate for Cushing’s disease and congenital adrenal hyperplasia as well as its sst5 agonist development candidate for congenital hyperinsulinemia towards the clinic as IND enabling activities for both programs are underway
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
+1.1%
Avg return
Earnings day
+1.4%
Avg return
5 days after
-1.0%
Avg return
30 days after
45%
14 / 31 earnings
Positive
+14.8%
Q2 2020
Best reaction
-13.0%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | -11.5% | -21.1% | |
| Q4 2025 | -6.1% | -9.7% | -23.0% | |
| Q3 2025 | -8.0% | -1.5% | +7.3% | |
| Q1 2025 | -6.2% | -4.3% | +0.9% | |
| Q4 2024 | +7.7% | +2.2% | +4.6% | |
| Q3 2024 | -1.8% | -8.8% | -7.3% | |
| Q2 2024 | -1.4% | +4.2% | +4.3% | |
| Q1 2024 | -5.7% | -3.0% | -12.1% | |
| Q4 2023 | +1.2% | +7.5% | +15.7% | |
| Q3 2023 | -6.7% | -11.7% | +9.8% | |
| Q2 2023 | -7.3% | -8.3% | -10.2% | |
| Q1 2023 | +3.6% | +9.4% | +2.0% | |
| Q4 2022 | +2.2% | -0.3% | -17.6% | |
| Q3 2022 | -0.8% | -3.0% | -11.4% | |
| Q2 2022 | +8.6% | +4.3% | +2.1% | |
| Q1 2022 | +11.2% | +26.2% | +10.3% | |
| Q4 2021 | +11.6% | +25.3% | +3.3% | |
| Q3 2021 | +0.7% | -0.8% | -10.7% | |
| Q2 2021 | +13.3% | +31.9% | +40.8% | |
| Q1 2021 | -0.7% | -3.2% | -0.8% | |
| Q4 2020 | -0.7% | +4.0% | +15.4% | |
| Q3 2020 | -7.8% | -1.2% | -2.6% | |
| Q2 2020 | +14.8% | +3.4% | -5.3% | |
| Q1 2020 | +14.3% | +14.8% | -5.8% | |
| Q4 2019 | -13.0% | -33.2% | -33.1% | |
| Q3 2019 | -0.4% | -3.6% | +13.3% | |
| Q2 2019 | -4.5% | -0.6% | -8.1% | |
| Q1 2019 | -2.3% | +0.8% | -12.8% | |
| Q4 2018 | +8.1% | +8.1% | -0.3% | |
| Q3 2018 | +8.8% | +8.5% | +27.9% | |
| Q2 2018 | -2.9% | -2.5% | -7.2% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro